Ignite Creation Date:
2024-05-06 @ 11:05 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03420742
Status:
COMPLETED
Last Update Posted:
2023-01-27
First Post:
2018-01-29
Brief Title:
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Sponsor:
Takeda
Organization:
Takeda
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-06-26
Start Date Type:
ACTUAL
Primary Completion Date:
2020-03-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-04-29
Completion Date Type:
ACTUAL
First Submit Date:
2018-01-29
First Submit QC Date:
January 29 2018
Study First Post Date:
2018-02-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2023-01-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-04-22
Last Update Post Date:
2023-01-27
Last Update Post Date Type:
ACTUAL